坦索罗辛与阿夫唑嗪对良性前列腺增生患者生活质量和性功能的影响  

Effects of tamsulosin and alfuzosin on quality of life and sexual function in patients with benign prostatic hyperplasia

作　　者：胡赛峰 胡安定 钱挺照 Sai-Feng HU;An Ding HU;Ting-Zhao QIAN(Department of Urology,Yongkang Traditional Chinese Medicine Hospital,Yongkang 321300,Zhejiang Province,China)

机构地区：[1]永康市中医院泌尿外科,浙江永康321300

出　　处：《中国药师》2023年第10期111-118,共8页China Pharmacist

基　　金：浙江省科技计划项目(2019C03002)。

摘　　要：目的良性前列腺增生是常见的老年男性生殖器官疾病。临床早期治疗干预对良性前列腺增生至关重要。本研究旨在比较坦索罗辛与阿夫唑嗪在良性前列腺增生中的疗效差异,为临床合理用药提供参考。方法回顾性分析2020年1月至12月永康市中医院泌尿外科收治的良性前列腺增生患者,分别接受盐酸坦索罗辛缓释胶囊(坦索罗辛组)和盐酸阿夫唑嗪缓释片(阿夫唑嗪组)口服治疗。比较两组治疗前后前列腺症状评分(IPSS)、国际勃起功能指数(IIEF)、最大尿流量(MFR)、膀胱残尿量(Ru)、前列腺体积(PV)、生活质量(SF-36量表)和治疗有效率对临床疗效进行评估;比较肝功能[丙氨酸转移酶(ALT)、天冬氨酸转移酶(AST)、总胆红素]、肾功能[血尿素氮(BUN)和血肌酐(Cr)]、前列腺肿瘤标志物血清游离前列腺特异性抗原(F-PSA)和血清总前列腺特异性抗原(T-PSA),对安全性进行评估。结果共纳入良性前列腺增生患者106例(坦索罗辛组55例,阿夫唑嗪组51例)。与治疗前相比,两组患者治疗后(治疗后6个月、12个月和24个月)IPSS、Ru和PV显著降低(P<0.05),生活质量显著上升(P<0.05)。与阿夫唑嗪组相比,治疗后坦索罗辛组患者(治疗后6个月、12个月和24个月)IPSS、Ru和PV显著降低(P<0.05),而IIEF、MFR和生活质量显著增高(P<0.05)。坦索罗辛组治疗总有效率显著高于阿夫唑嗪组(92.73%vs.78.43%,P=0.035)。治疗前后两组患者肝肾功能和前列腺标志物均无显著变化(P>0.05),且均处于正常范围。结论坦索罗辛和阿夫唑嗪均可有效改善良性前列腺增生症状,并提高患者生活质量,具有良好的安全性。此外,较阿夫唑嗪而言,坦索罗辛对良性前列腺患者的治疗效果更为显著。Objective Benign prostatic hyperplasia(BPH)is a common reproductive organ disease in elderly men.Early adoption of appropriate treatment methods in clinical practice is crucial for the treatment of benign prostatic hyperplasia.This study aimed to compare the therapeutic effects of tamsulosin and alfuzosin on benign prostatic hyperplasia and provide references for clinical rational drug use.Method A retrospective analysis was conducted on patients with benign prostatic hyperplasia admitted to Yongkang Hospital of Traditional Chinese Medicine from January 2020 to December 2020.The patients in the tamsulosin group received oral tamsulosin hydrochloride sustained-release capsules,while the patients in the alfuzosin group received alfuzosin hydrochloride sustained-release tablets.The international prostate symptom score(IPSS),international erectile function index(IIEF),maximum urinary flow(MFR),bladder residual urine volume(RU),prostate volume(PV),quality of life(SF-36 scale),and treatment effectiveness before and after treatment were compared to evaluate clinical efficacy.Liver function[alanine transferase(ALT),aspartate transferase(AST),total bilirubin],renal function[blood urea nitrogen(BUN)and creatinine(Cr)],prostate tumor markers serum free prostate specific antigen(F-PSA),and serum total prostate specific antigen(T-PSA)before and after treatment were compared to evaluate the safety.Result 106 patients with benign prostatic hyperplasia were included(55 cases in tamsulosin group and 51 cases in alfuzosin group).Compared to before treatment,IPSS,RU and PV of the patients in the two groups after 6 months,12 months,and 24 months of treatment were significantly decreased(P<0.05),and the quality of life were significantly increased(P<0.05).Compared with alfuzosin group,patients in tamsulosin group showed a significant decrease in IPSS,Ru and PV after 6 months,12 months,and 24 months of treatment(P<0.05)and an increase in IIEF,MFR and quality of life(P<0.05).The total effective rate of the Tamsulosin group was signific

关 键 词：良性前列腺增生 坦索罗辛 阿夫唑嗪 

分 类 号：R697.3[医药卫生—泌尿科学]